Investors

Key press releases

14 Mar 2023
17:00 E.S.T.

Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting

08 Mar 2023
16:45 E.S.T.

Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

06 Mar 2023
16:30 E.S.T.

Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update

Key upcoming events

09 Mar 2023

Cellectis to hold fourth quarter and year-end 2022 earnings call on March 9, 2023 at 8AM ET

Learn more

Key corporate presentation

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

$1.9700

-0.0650 (-3.1941%)

Prev. close: 2.0350
Volume: 392,894
High: 2.0900
Capitalization: 109.502M

€1.8240

-0.1190 (-6.1245%)

Prev. close: 1.9430
Volume: 166,698
High: 1.9940
Capitalization: 101.385M

See stock information

Covering research analysts

Barclays - Gena Wang

Citi - Yigal Nochomovitz

Goldman Sachs - Salveen Richter

Jefferies - Kelly Shi

JMP Securities - Silvan Tuerkcan

Jones Trading - Soumit Roy

Kempen - Sebastiaan van der Schoot

Oddo BHF - Martial Descoutures

Oppenheimer – Hartaj Singh

RW Baird - Jack Allen

Wells Fargo – Yanan Zhu

William Blair – Raju Prasad

SMBC - David Dai

Cellectis contact information

Arthur Stril, Chief Business Officer

Ashley R. Robinson, LifeSci Advisors

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89